EntryPoint Capital LLC Increases Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

EntryPoint Capital LLC boosted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 23.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 10,923 shares of the biopharmaceutical company’s stock after purchasing an additional 2,098 shares during the period. EntryPoint Capital LLC’s holdings in Cytokinetics were worth $514,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jones Financial Companies Lllp boosted its position in shares of Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Cytokinetics by 0.4% during the third quarter. MetLife Investment Management LLC now owns 123,308 shares of the biopharmaceutical company’s stock valued at $6,511,000 after buying an additional 538 shares during the last quarter. Retirement Systems of Alabama lifted its position in Cytokinetics by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 143,495 shares of the biopharmaceutical company’s stock valued at $6,750,000 after purchasing an additional 565 shares during the last quarter. Arizona State Retirement System boosted its position in Cytokinetics by 1.9% during the 4th quarter. Arizona State Retirement System now owns 32,366 shares of the biopharmaceutical company’s stock valued at $1,522,000 after buying an additional 600 shares during the period. Finally, Inspire Investing LLC increased its holdings in Cytokinetics by 7.8% during the 4th quarter. Inspire Investing LLC now owns 8,504 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 616 shares during the period.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 2,775 shares of Cytokinetics stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.38, for a total transaction of $123,154.50. Following the completion of the sale, the executive vice president now directly owns 34,888 shares in the company, valued at $1,548,329.44. This trade represents a 7.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total value of $98,640.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at approximately $5,724,621.72. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,834 shares of company stock worth $1,949,275 in the last 90 days. Corporate insiders own 3.40% of the company’s stock.

Cytokinetics Stock Up 2.5 %

NASDAQ:CYTK opened at $46.57 on Tuesday. The company’s 50-day simple moving average is $45.96 and its 200-day simple moving average is $49.82. The stock has a market capitalization of $5.51 billion, a P/E ratio of -8.66 and a beta of 0.95. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics, Incorporated has a fifty-two week low of $40.53 and a fifty-two week high of $75.71.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million. On average, equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Stifel Nicolaus started coverage on Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a report on Thursday, February 6th. HC Wainwright reissued a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a research report on Friday, February 28th. Finally, Royal Bank of Canada upped their price target on Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus price target of $82.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.